Aspire Biopharma Holdings, INC. (ASBP) — SEC Filings
Latest SEC filings for Aspire Biopharma Holdings, INC.. Recent 8-K filing on Apr 20, 2026. AI-decoded analysis of earnings, risk factors, and insider trade
View Aspire Biopharma Holdings, INC. on SEC EDGAR
Overview
Aspire Biopharma Holdings, INC. (ASBP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Apr 17, 2026: Aspire Biopharma Holdings, Inc. filed an amendment (8-K/A) on April 17, 2026, to its previous filing. This amendment pertains to Item 1.01 (Entry into a Material Definitive Agreement) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), indicating changes or upda
Sentiment Summary
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant filing sentiment for Aspire Biopharma Holdings, INC. is neutral.
Filing Type Overview
Aspire Biopharma Holdings, INC. (ASBP) has filed 3 8-K, 1 8-K/A, 1 EFFECT, 1 10-K/A with the SEC between Apr 2026.
Recent Filings (6)
- 8-K Filing — 8-K · Apr 20, 2026
-
Aspire Biopharma Files 8-K/A Amendment
— 8-K/A · Apr 17, 2026 Risk: medium
Aspire Biopharma Holdings, Inc. filed an amendment (8-K/A) on April 17, 2026, to its previous filing. This amendment pertains to Item 1.01 (Entry into a Materia - 8-K Filing — 8-K · Apr 16, 2026
- 8-K Filing — 8-K · Apr 15, 2026
-
Aspire Biopharma Holdings SEC Filing Effectiveness
— EFFECT · Apr 15, 2026 Risk: low
Aspire Biopharma Holdings, Inc. filed an EFFECT form with the SEC on April 15, 2026, indicating the effectiveness of a registration statement. The effectiveness -
Aspire Biopharma Files Amended 2025 Annual Report
— 10-K/A · Apr 8, 2026 Risk: low
Aspire Biopharma Holdings, Inc. filed an amended 10-K report on April 8, 2026, for the fiscal year ending December 31, 2025. The filing includes various exhibit
Risk Profile
Risk Assessment: Of ASBP's 3 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 2 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
amendment (2) · corporate-governance (1) · material-agreement (1) · registration-statement (1) · effectiveness (1) · filing (1) · annual-report (1) · pharmaceuticals (1)
Key Numbers
- Filing Acceptance Date: 2026-04-15 — Date the EFFECT filing was accepted by the SEC.
- Effectiveness Date: 2026-04-14 — Date the registration statement became effective.
- iXBRL 10-K/A Size: 2265424 — Size of the main 10-K/A filing document in bytes.
- Complete submission text file Size: 8568196 — Size of the complete submission text file in bytes.
Frequently Asked Questions
What are the latest SEC filings for Aspire Biopharma Holdings, INC. (ASBP)?
Aspire Biopharma Holdings, INC. has 6 recent SEC filings from Apr 2026, including 3 8-K, 1 8-K/A, 1 EFFECT. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ASBP filings?
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant sentiment is neutral.
Where can I find Aspire Biopharma Holdings, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aspire Biopharma Holdings, INC. (ASBP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aspire Biopharma Holdings, INC.?
Financial highlights for Aspire Biopharma Holdings, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for ASBP?
Investment thesis data for ASBP will be available once enriched filings are processed.
Who are the key executives at Aspire Biopharma Holdings, INC.?
Executive information for Aspire Biopharma Holdings, INC. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Aspire Biopharma Holdings, INC. stock?
Of ASBP's 3 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 2 low-risk.
What are recent predictions and forward guidance from Aspire Biopharma Holdings, INC.?
Forward guidance and predictions for Aspire Biopharma Holdings, INC. are extracted from SEC filings as they are enriched.